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Nutritional excess and hyperlipidemia increase the heart’s 
susceptibility to ischemic injury. Mammalian target of rapamycin 
(mTOR) controls the cellular response to nutritional status 
and may play a role in ischemic injury. To explore the effect of 
hypercholesterolemia on cardiac mTOR signaling, we assessed 
mTOR signaling in hypercholesterolemic swine (HC) that are 
also susceptible to increased cardiac ischemia-reperfusion injury. 
Yucatan pigs were fed a high-fat/high-cholesterol diet for 4 
weeks to induce hypercholesterolemia, and mTOR signaling 
was measured by immunoblotting and immunofluorescence in 
the non-ischemic left ventricular area. Total myocardial mTOR 
and raptor levels were markedly increased in the HC group 
compared to the normocholesterolemic group, and directly 
correlated with serum cholesterol levels. mTOR exhibited 
intense perinuclear staining in myocytes only in the HC group. 
Hypercholesterolemia was associated with hyperactive signaling 
upstream and downstream of both mTOR complexes, including 
myocardial Akt, S6K1, 4EBP1, S6 and PKC-alpha, increased 
levels of cardiac hypertrophy markers, and a trend toward lower 
levels of myocardial autophagy. Hypercholesterolemia can now 
be added to the growing list of conditions associated with aber-
rant mTOR signaling. Hypercholesterolemia produces a unique 
profile of alterations in cardiac mTOR signaling, which is a 
potential target in cardiac diseases associated with hypercholes-
terolemia and nutritional excess.
Introduction
Hyperlipidemia is one of the most common risk factors for 
coronary heart disease, and is associated with increased morbidity 
and mortality from cardiac events and procedures.1,2 Major 
studies have shown that diet, particularly those high in saturated 
fat, also plays a fundamental role in cardiovascular risk.3 We 
recently showed a 45% greater myocardial infarct after ischemia-
reperfusion (I/R) in hypercholesterolemic pigs fed a high-fat/
high-cholesterol diet for four weeks,4 which is much shorter than 
the time needed to produce atherosclerosis.5 Fortunately, mortality 
from cardiovascular disease has declined drastically in the last 50 
years due to decreases in serum cholesterol and the modification 
of other risk factors. Experts believe, however, that this trend has 
slowed due to unhealthy eating patterns in the majority of the US 
population, specifically with respect to the overconsumption of 
energy-rich foods.6
Mammalian target of rapamycin (mTOR) plays a central role 
in integrating the cell’s response to nutritional status, including 
intracellular ATP, glucose and amino acid levels.7 Hyperactivation 
of mTOR has been shown to increase most organs’ sensitivity to 
oxidative stress.8 The etiology of many diseases associated with 
aging has been attributed to increased oxidative stress and more 
recently, to hyperactivation of mTOR through multiple mecha-
nisms including nutrient excess.9 mTOR exists in mTOR complex 
1 (mTORC1) with raptor and mTOR complex 2 (mTORC2) 
with rictor. mTORC1 is activated by Akt and inhibited by AMPK, 
and promotes protein synthesis and leads to cardiac hypertrophy 
through its activation of S6K1 and S6, and inhibition of 4EBP1 
and autophagy. mTORC2 activates Akt and PKCα, and may also 
contribute to cardiac hypertrophy.10 While some studies have 
shown that prior activation of Akt or S6K1 are important for 
cell survival after I/R,11,12 others have suggested that rapamycin 
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induces a metabolic state that protects cardiomyocytes from I/R 
injury.10,13,14
The effect of hypercholesterolemia on mTOR signaling has 
not been studied. We examined mTORC1 and 2 signaling in pigs 
fed a high cholesterol diet for 4 weeks, in order to study the effect 
of hypercholesterolemia on myocardial signaling independent of 
secondary effects related to atherosclerosis and underlying ischemia. 
Since hypercholesterolemia is likely produced through the complex 
interplay of dietary and genetic factors, a large animal model was 
used that may be more applicable to patients than traditional 
rodent models.15 Here we describe that hyperactive myocardial 
mTOR signaling is present in early hypercholesterolemia, and 
implicate mTOR complex 1 and 2 signaling in altering myocardial 
metabolism and susceptibility to ischemic injury.
Results
Biochemical parameters and body weight. The high-fat/
high-cholesterol diet induced significant elevations in serum total 
cholesterol, LDL and HDL in the HC group (p < 0.01 for all; 
Table 1). Triglycerides tended to be slightly higher in the HC 
group (p = 0.051), and body weight was similar between groups. 
Some pigs in the HC group displayed elevations in serum glucose 
and insulin levels, but the differences were not significant, and 
HOMA-IR, a measure of insulin resistance,16 tended to be higher 
in the HC group (data not shown).
mTORC1 and 2 components. mTOR levels were increased 
by about 3-fold in the HC group (p < 0.01), and raptor levels 
were increased by more than 5-fold in the HC group (p < 0.01). 
In contrast, levels of rictor and mLST8 were not significantly 
different between groups (p = 0.4 and p = 0.8, respectively; Fig. 1). 
mTOR and raptor levels exhibited strong direct correlations with 
serum total cholesterol and HDL levels (Table 2; for correlation 
plots see Suppl. Fig. 1). mTOR and raptor levels exhibited modest 
and strong direct correlations with serum LDL, respectively. 
There was no correlation between mTOR and raptor levels and 
triglycerides or body weight. mTOR levels also showed a modest 
correlation with insulin levels and HOMA-IR measurements, 
while raptor levels showed no correlation with any measures of 
insulin resistance (data not shown).
Signaling upstream of mTORC1. The phosphorylation of Akt 
at Thr308, as measured by the ratio of phospho-to-total levels of 
the protein, tended to be higher in HC group (p = 0.052; Fig. 2). 
PRAS40 phosphorylation at Thr246 and mTOR phosphorylation 
at Ser2448 were higher in the HC group (p < 0.05 and p < 0.01, 
respectively). Total levels of Akt did not change (p = 0.6), while 
total levels of PRAS40 tended to be slightly lower in the HC group 
(p = 0.14). AMPKα phosphorylation at Thr172 was significantly 
lower in the HC group (p < 0.01; Fig. 3), while levels of total 
AMPKα were slightly higher in the HC group (p = 0.19). Levels 
of Rheb were lower in the HC group (p < 0.05), while there was no 
difference in REDD1 levels between the groups (p = 0.3).
mTORC1 activity. The phosphorylation of 4EBP1 at Thr37/46 
and S6K1 at Thr389 was increased by more than 2-fold in the 
HC group (p < 0.01 and p < 0.05, respectively; Fig. 4), and S6 
phosphorylation at Ser240/244 was significantly higher in the HC 
group (p < 0.05). However, total levels of 4EBP1, S6K1 and S6 
were unchanged (p = 0.4, 0.6 and 1, respectively).
mTORC2 activity. The phosphorylation of Akt at Ser473 was 
significantly higher in the HC group (p < 0.05; Fig. 5). As measured 
by a pan-PKC antibody with reactivity to Ser657 of PKCα, the phos-
phorylation of a PKC isoform at the same molecular weight as PKCα 
was increased by more than 2-fold in the HC group (p < 0.01), and 
levels of PKCα were also higher in the HC group (p < 0.01).
Immunolocalization of mTOR. Immunofluorescence studies 
showed that mTOR was highly expressed in myocytes (Fig. 6), 
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Table 1 Lipid profile and body weight
 NC HC p
Chol (mmol/L) 1.61 ± 0.27 13.8 ± 1.8 <0.01
LDL (mmol/L) 0.53 ± 0.05 5.46 ± 0.74 <0.01
HDL (mmol/L) 0.53 ± 0.06 1.81 ± 0.11 <0.01
TG (mmol/L) 0.30 ± 0.14 0.33 ± 0.03 0.051
Body Weight (kg) 22.4 ± 1.5 21.4 ± 0.9 0.54
Yucatan pigs were fed a normocholesterolemic (NC, n=6) or a high-fat/high-cholesterol diet (HC, n=7) 
for 4 weeks. Serum total cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), triglycerides (TG) and body weight were measured. Values are expressed as mean ± SEM, with 
corresponding p values.
Figure 1. Hypercholesterolemia is associated with significantly higher lev-
els of cardiac mTOR and raptor. Representative western blots for mTOR, 
raptor, rictor, mLST8 and α-tubulin in the left ventricle of hypercholester-
olemic (HC) and normocholesterolemic (NC) pigs, and quantification of 
the data. Bands were rearranged from the original gel for clarity of presen-
tation. Densities were calculated relative to total Ponceau S staining. Data 
are expressed as mean ± SEM. **p < 0.01 versus control.
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(Suppl. Fig. 2A). mTOR did not co-localize in the HC group 
with SERCA2 ATPase, a marker for the sarcoplasmic reticulum/
endoplasmic reticulum (Suppl. Fig. 2B).
Cardiac hypertrophy and autophagy. Total levels of β-actin, 
troponin I, troponin T and SERCA2 ATPase were significantly 
increased in the HC group (p < 0.05 for all; Fig. 7), while levels 
of α-tubulin did not change (p = 0.7). The ratio of LC3B II/I also 
tended to be lower in the HC group (p = 0.08).
Correlation between biochemical parameters and mTORC1 
and 2 signaling. The ratio of phospho-to-total mTOR, 4EBP1, 
Akt (Ser473) and total Rheb, PKCα, and SERCA2 ATPase 
directly correlated with serum total cholesterol and LDL levels (See 
Suppl. Table 1). The ratio of phospho-to-total AMPK inversely 
correlated with serum total cholesterol, LDL and HDL. None 
of the measured proteins or phosphorylated proteins exhibited a 
correlation with triglycerides or body weight, except total PKCα 
and troponin T, which directly correlated with triglycerides 
(Suppl. Table 1).
Discussion
Hypercholesterolemia is a major risk factor for coronary artery 
disease, myocardial infarction and adverse outcomes after isch-
emic events.1 It is also associated with cardiac hypertrophy.17 We 
demonstrate that early hypercholesterolemia in pigs increased total 
levels of mTOR and raptor and activated mTORC1 signaling. 
We show that mTORC2 signaling was activated since Akt and 
PKCα signaling was increased. The hypercholesterolemic pigs also 
showed higher levels of cardiac hypertrophy markers and a trend 
toward inhibition of autophagy in the myocardium. These find-
ings carry important implications for the role of mTOR in altering 
cardiac metabolism in hypercholesterolemia, and may influence 
the heart’s response to ischemia.
Hypercholesterolemia activated mTORC1 through several 
mechanisms. Total levels of mTOR and raptor were increased and 
directly correlated with serum cholesterol, indicating that may 
be novel sensors to cholesterol levels. This occurred through an 
as-yet-undefined mechanism since levels of FOXO1 and 4EBP1, 
the only molecules known to regulate mTOR and raptor expres-
sion,18 were not changed (for FOXO1, see Suppl. Fig. 3A). In 
addition, Akt and AMPK were upstream mediators leading to 
activation of mTORC1. Akt was more phosphorylated on Thr308 
and Ser473 in the HC group, and the mTORC1 inhibitor 
PRAS40 was more phosphorylated on Thr246, indicating that 
Akt contributed to mTOR activation via PRAS40 inhibition.19 
The higher Ser2448 phosphorylation of mTOR also indicated that 
mTORC1 was more activated by Akt in the HC group, although 
S6K1 may also phosphorylate this site.20 AMPK, a key negative 
regulator of mTORC1,7 was less active (less phosphorylated on 
Thr172) in the HC group. Akt is sequentially activated, first by the 
 phosphorylation of Thr308 by PDK1 through PI3K signaling, and 
then fully activated by mTORC2’s phosphorylation of Ser473.21 
AMPK was likely inhibited by the high intracellular energy status 
in the HC group, since fatty acids are a principal source of energy 
to cardiomyocytes,22 and AMPK is inhibited by a high intracel-
lular ATP/AMP ratio.23
and could not be detected in other cardiac cell types, such as the 
vascular endothelium or smooth muscle. Of the 3 animals exam-
ined from each group, all of the HC animals exhibited mTOR 
staining in a punctate perinuclear distribution, whereas staining 
for mTOR in the ND animals was diffusely cytoplasmic when 
detectable. A similar cellular expression and distribution was seen 
for phospho-S6K1 (data not shown). To confirm the specificity 
of the mTOR antibody, we incubated the mTOR antibody 
with a blocking peptide, and this eliminated mTOR staining 
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Table 2  Corrleation of lipid profile and body weight 
with cardiac mTOR and raptor levels
       mTOR       raptor 
 r p r p
Chol 0.57 <0.05 0.81 <0.001
LDL 0.53 0.06 0.77 <0.01
HDL 0.72 <0.01 0.81 <0.001
TG 0.24 0.41 0.33 0.27
Body Weight 0.08 0.79 0.05 0.86
Yucatan pigs were fed a normal or high-fat/high-cholesterol diet for 4 weeks. Left ventricular mTOR 
and raptor levels were measured by immunoblotting. Serum total cholesterol (Chol), low-density lipo-
protein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and body weight were also measured. 
Correlation (r) with corresponding p values are shown. For correlation plots, see Supplemental Figure 1.
Figure 2. Hypercholesterolemia is associated with increased in car-
diac Akt/mTOR signaling. Representative western blots for phospho-Akt 
(Thr308), phospho-PRAS40 (Thr246), phospho-mTOR (Ser2448), and 
total levels of Akt, PRAS40 and α-tubulin in the left ventricle of hypercho-
lesterolemic (HC) and nomocholesterolemic (NC) pigs, and quantification 
of the data. The phospho-mTOR blot corresponds to the total mTOR blot 
shown in Figure 1. Bands were rearranged from the original gel for clar-
ity of presentation. Densities were calculated relative to total Ponceau S 
staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio 
of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 
0.01 versus control.
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Other upstream modulators of mTORC1 activity were also 
altered in hypercholesterolemia, including Rheb, another nutrient-
stimulated activator of mTORC1,7 which was decreased in the 
HC group. We also measured REDD1, which has been shown to 
be induced by oxidative stress,24 but it showed no change in the 
HC group, even though hypercholesterolemia is associated with 
chronic oxidative stess.25 However, the major downstream targets 
of mTORC1, 4EBP1 and S6K1, were hyperphosphorylated in 
the HC group, indicating that mTORC1 was activated in the HC 
group, likely due to both overexpression of mTOR and raptor 
as well as stimulation of upstream signaling, including Akt and 
AMPK. These sites (Thr36/47 on 4EBP1 and Thr389 on S6K1) 
are classic measures of mTORC1 activity.26 We also observed 
intense punctate perinuclear staining for mTOR in the HC group 
compared to diffuse cytoplasmic staining when detectable in 
the ND group. This is consistent with a similar shift in mTOR 
staining observed in human cells in vitro when mTORC1 was 
stimulated with amino acids, further suggesting that mTORC1 
was activated in our model.27 Combined with the phospho-S6K1 
immunostaining, this indicates that myocytes were the primary cell 
type contributing to the hyperactive mTOR signaling in pigs fed a 
high-fat/high-cholesterol diet. mTOR did not colocalize with the 
sarcoplasmic reticulum/endoplasmic reticulum in the HC group,24 
as it is believed to localize in some cell types,28 and whether any 
organelles, such as mitochondria, are mainly affected by the 
increased mTOR signaling/expression in hypercholesterolemia, 
remains to be elucidated.
Figure 3. Effect of hypercholesterolemia on upstream modulators of 
mTORC1 in the myocardium. Representative western blots for phospho-
AMPKα (Thr172), AMPKα, Rheb, REDD1 and α-tubulin in the left ventricle 
of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and 
quantification of the data. Bands were rearranged from the original gel for 
clarity of presentation. Densities were calculated relative to total Ponceau 
S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio 
of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p 
<0.01 versus control.
Figure 4. Hypercholesterolemia is associated with increased phosphoryla-
tion of cardiac mTORC1 targets. Representative western blots for phospho-
4EBP1 (Thr37/46), phospho-S6K1 (Thr389), phospho-S6 (Ser240/244), 
total levels of these proteins, and α-tubulin in the left ventricle of hypercho-
lesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification 
of the data. Bands were rearranged from the original gel for clarity of 
presentation. Densities were calculated relative to total Ponceau S stain-
ing. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the 
protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01 
versus control.
We showed that hypercholesterolemia also activated myocardial 
mTORC2. Total levels of rictor, a key component of mTORC2,29 
and mLST8, a component common to both complexes, were not 
altered in hypercholesterolemia. However, the phosphorylation 
of Akt on Ser473 and PKCα on Ser657 were increased in the 
HC group. These residues are the main sites phosphorylated by 
mTORC2.21 mTORC2 also increases the stability of PKCα,30 and 
total levels of PKCα were higher in the HC group. The activity of 
mTORC2 may have been increased by the higher levels of mTOR 
in hypercholesterolemia, or still unknown upstream mediators. 
The major substrates of mTORC2 are Akt, which further activates 
mTORC1, and PKCα, which affects microvascular function and 
cardiac contractility.
Hypercholesterolemia and diets high in saturated fat are 
independent risk factors for the development of left ventricular 
hypertrophy, which heavily influences morbidity and mortality 
from cardiovascular disease.17 The HC pigs displayed increased 
markers of cardiac hypertrophy, which is significant in light of 
the changes observed in mTOR signaling. mTORC1  regulates 
the development of cardiac hypertrophy, primarily via promo-
tion of protein synthesis in myocytes.31-33 We observed enhanced 
phosphorylation of the ribosomal protein S6 in the HC group, 
and when coupled with the increased phosphorylation of 4EBP1, 
a translational inhibitor in its nonphosphorylated form, this 
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cardiac I/R.44 Our study is the first to suggest that hyperactivation 
of the mTOR pathway through dietary modifications in a large 
animal model may sensitize the myocardium to I/R injury.
Hyperactive mTOR signaling may increase myocardial suscep-
tibility to ischemic injury in several ways (Fig. 8). Decreasing 
myocardial energy demand is a major strategy for reducing I/R 
injury during acute myocardial infarction. mTORC1 instead 
increases energy demand by activating translation and promoting 
the development of a hypertrophic, hypercontractile phenotype. 
In fact, inhibition of protein synthesis, in part through HIF-1α-
mediated downregulation of mTOR signaling,45 has been shown to 
protect cells from hypoxia by reducing mTOR-mediated stimula-
tion of translation. We observed a potential activation of translation 
in both the ischemic and non-ischemic myocardial territories of 
the HC group, including lower levels of HIF-1α, in conjunction 
with higher S6K1 levels, which activates the ribosomal protein S6, 
in the ischemic myocardial territory (Suppl. Fig. 3B). Similarly, 
these HC pigs demonstrated hyperdynamic cardiac function 
throughout the entire I/R event, including increased developed left 
ventricular pressure, peak systolic function, and mean arterial pres-
sure (MAP).4 On a molecular level, the activation of mTORC1 
in the HC group also inhibited autophagy, an important cellular 
process for degrading old organelles and proteins,46 as indicated by 
the lower ratio of LC3B-II/I, a marker of autophagy.47 Combined 
with increased protein synthesis, the activation of mTORC1 may 
have led not only to a hypertrophic, hyperdynamic phenotype, 
but also to the accumulation of misfolded proteins and damaged 
mitochondria in the HC myocardium, increasing its susceptibility 
to ischemia.48,49
mTORC2 may also play a role in ischemic injury through its 
activation of PKCα and Akt. PKCα contributes to microvascular 
dysfunction and I/R injury, especially in the setting of hypercho-
lesterolemia.50,51 Akt may also contribute to the metabolic effects 
of hypercholesterolemia on the myocardium, since it promotes the 
intracellular transport of glucose and lipids52,53 and further acti-
vates mTORC1. We hypothesize that this coactivation of cardiac 
mTORC1 and 2 perpetuates a hyperactive energy supply-and-
demand cycle in the hypercholesterolemic myocardium, increasing 
its susceptibility to the withdrawal of nutrients and oxygen upon 
ischemia.
In conclusion, our study highlights a role for cardiac mTORC1 
and 2 signaling in nutritional excess, hypercholesterolemia and 
ischemic injury. It cannot (1) refute the possibility that hemo-
dynamic stress, due to a high MAP or the acute I/R event also 
activated mTOR signaling in the non-ischemic left ventricle; 
nor (2) provide direct evidence that hypercholesterolemia specifi-
cally activates mTORC1 and 2 in myocytes. Instead, we used a 
clinically-relevant porcine model of diet-induced hypercholes-
terolemia, which is known to produce multiple changes similar 
to the metabolic syndrome in humans.15 These pigs had slight 
hypertension, slight hypertriglyceridemia, and likely metabolic 
changes in other organs that may have also contributed to the 
alterations we observed in cardiac mTORC1 and 2 signaling. This 
is a strength and not a weakness of our study since it implicates 
hyperactive mTORC1 and 2 signaling in the cardiac pathologies 
associated with a high-fat/high-cholesterol diet, and correlates 
indicates a trend toward increased protein synthesis in the 
hypercholesterolemic myocardium. mTORC2 also plays a role 
in cardiac hypertrophy,10 since it controls the actin cytoskeleton 
and activates Akt and PKCα, which has been shown to maintain 
contractile force by associating with troponin I in myocytes.34 The 
effect of mTOR on the expression of both fetal and constitutive 
hypertrophy genes is not well understood. However mTORC1 
and 2 may contribute to the hypertrophic changes observed in the 
hypercholesterolemic myocardium.
Hypercholesterolemia is a prevalent condition in patients with 
ischemic heart disease, and influences outcomes after cardiac events 
and procedures.1,2 Previous studies have focused on microvascular 
and endothelial dysfunction as an explanation for hypercholester-
olemia’s adverse cardiac effects.35,36 However, metabolic conditions 
within myocytes influence the heart’s response to ischemic injury 
and are altered by major cardiovascular risk factors.37,38 The hyper-
cholesterolemic pigs in our study exhibited a 45% greater infarct 
after ischemia-reperfusion than control pigs,4 after only four weeks 
of feeding with a hypercholesterolemic diet that also activated 
mTOR. Constitutive activation of mTOR has been shown both in 
vitro and in vivo to induce necrosis, apoptosis and autophagic cell 
death upon nutrient deprivation and hypoxia,39-43 and transgenic 
mice with chronic activation of Akt displayed a larger infarct after 
Figure 5. Hypercholesterolemia is associated with increased phosphoryla-
tion of mTORC2 targets, and an increase in PKCα levels in the myocardi-
um. Representative western blots for phospho-Akt (Ser473), phospho-PKC 
(α, Ser657), total PKCα and α-tubulin in the left ventricle of hypercholes-
terolemic (HC) and normocholesterolemic (NC) pigs, and quantification of 
the data. For total levels of Akt corresponding to the phospho-Akt (Ser473) 
blot, see Figure 2. The phospho-PKC antibody was a phospho-pan PKC 
antibody with reactivity to PKCα when phosphorylated at Ser657. This is 
the thicker bottom band which overlapped with total PKCα. Bands were 
rearranged from the original gel for clarity of presentation. Densities were 
calculated relative to total Ponceau S staining. Phosphorylation is pre-
sented as the phospho-to-total (p/t) ratio of the protein. Data are expressed 
as mean ± SEM. *p < 0.05, **p < 0.01 versus control.
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demarcate the non-ischemic ventricular tissue before harvesting. 
Only non-ischemic tissue was used in this study. Tissue was rapidly 
frozen in liquid nitrogen and stored at -80°C for use in western 
blotting. Tissue was fixed in 10% formaldehyde for 3 hours 
followed by 20% sucrose overnight at 4°C, mounted in tissue 
blocks with OCT (Sakura Finetek, Torrance, CA), and frozen at 
-80°C for use in immunofluorescence studies.
Western blotting. Ventricular tissue from the non-ischemic 
territory was homogenized in 25 mL RIPA buffer consisting of 50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS (Boston Bioproducts, Worcester, MA), 
phosphatase inhibitor cocktails I and II at 1:100 (Sigma, St. Louis, 
MO), one-half tablet of Complete EDTA-free protease inhibitor 
cocktail (Roche, Indianapolis, IN) and 64 mM NaF (Fisher 
Scientific, Pittsburgh, PA). Protein concentration was quanti-
fied using the Micro BCA Protein Assay Kit (Pierce, Rockford, 
Illinois) and equal amounts of protein (35 to 40 ug) were 
subjected to SDS-PAGE on 4–20% polyacrylamide gels (Pierce, 
Rockford, Illinois). Proteins were transferred to PVDF membranes 
(Millipore, Bellerica, MA) at 40 V overnight. Membranes were 
stained with Ponceau S to ensure equal protein transfer and separa-
tion. Membranes were blocked in 5% blotting-grade milk (Biorad, 
Hercules, CA), washed in TBS with 0.05% Tween-20 (Boston 
Bioproducts), followed by incubations in primary and secondary 
antibodies and Supersignal West Pico Chemiluminescent Substrate 
(Pierce) according to the manufacturers’ recommendation.
Optical density values were obtained from X-ray films using a 
flat-bed scanner and ImageJ 1.4 software (National Institutes of 
novel changes in mTOR and raptor expression with cholesterol 
levels. Rapamycin, which dissociates mTOR from raptor and can 
inhibit both mTORC1 and 2, is already being used clinically in 
transplantation and drug-eluting stents. Given our findings, it 
is worth examining the potential utility of rapamycin as well as 
specific mTORC1 and 2 inhibitors in models of I/R, hypertrophy 
and heart failure, particularly in the setting of hypercholester-
olemia and other metabolic diseases.
Methods
Animals. At 20 weeks of age, seven intact male Yucatan mini-
swine were fed a normal diet (NC) consisting of standard Minipig 
Breeder Diet (Purina, St. Louis, MO), while seven were fed a 
hypercholesterolemic diet (HC) for 4 weeks that substituted 25% 
of the ND with 17.2% coconut oil, 2.3% corn oil, 4% cholesterol 
and 1.5% sodium cholate. Animals were housed individually and 
provided with laboratory chow and water ad libitum. All experi-
ments were approved by the Beth Israel Deaconess Medical Center 
Animal Care and Use Committee and the Harvard Medical Area 
Standing Committee on Animals. This investigation conforms with 
the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996).
Pigs were fasted for 12 hours prior to harvesting the tissue 
used in this study. They had undergone 1 hr. myocardial isch-
emia/2 hr. reperfusion of the left anterior descending coronary 
artery for another study,4 and monastryl blue dye (Engelhard 
Corp., Louisville, KY) was injected into the coronary arteries to 
Figure 6. Hypercholesterolemia is associated with perinuclear localization of mTOR within myocytes. Confocal microscopy of mTOR (yellow) in the left 
ventricle of hypercholesterolemic (HC, a–c) and normocholesterolemic (NC, d–f) pigs. Perinuclear localization of mTOR is indicated with red arrowheads. 
Sections were co-stained with 4',6'-diamidino-2-phenylindole (DAPI, blue). Representative images are shown for three pigs selected randomly from each 
group. Scale bar represents 10 μm.
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at settings for which incubation with secondary antibody alone 
showed no signal.
Antibodies. All antibodies and blocking peptide were obtained 
from Cell Signaling Technology (Beverly, MA) with the following 
exceptions: anti-α-tubulin and anti-HIF-1α from Sigma (St. Louis, 
MO), anti-REDD1 from Proteintech Group, Inc. (Chicago, IL), 
anti-PKCα and anti-β-actin HRP from Santa Cruz Biotechnology 
(Santa Cruz, CA), anti-troponin I and anti-troponin T from 
US Biologicals (Swampscott, MA), and peroxidase-conjugated 
anti-rabbit light-chain specific secondary antibody from Jackson 
Immunoresearch (West Grove, PA) for phospho-S6K1 blots. The 
Health, USA). All calculated densities were normalized to total 
Ponceau S staining intensity. Protein phosphorylation was assessed 
by dividing levels of the phosphorylated form of the protein by 
levels of its total expression. Expression levels are presented in 
arbitrary units as mean ± SEM. Samples were originally loaded in 
a different order, and bands from X-ray films were rearranged in 
the Figures for clarity of presentation.
Immunofluorescence. Three animals were analyzed randomly 
from each group. Ten μm frozen sections from the non-ischemic 
ventricular territory were washed in PBS for 5 min and treated 
with 1% SDS (Boston Bioproducts) for 5 min. Sections were 
washed 3 times before blocking in 1% BSA for 1 hr. An mTOR 
antibody (the same used in immunoblots) was added overnight at 
4°C, followed by 3 washes in PBS and incubation with anti-rabbit 
AlexaFluor 555 (Molecular Probes, Eugene, OR) for 30 min. 
Sections were washed again three times in PBS and mounted in 
Vectashield plus DAPI (Vector Labs, Burlingame, CA). Slides were 
viewed under a Zeiss LSM510 confocal microscope (Carl Zeiss 
MicroImaging Inc., Thornwood, NY). Negative controls consisted 
of adsorption of the mTOR antibody with a blocking peptide 
or skipping the primary antibody. The images shown were taken 
Figure 8. Proposed role of mTORC1 and 2 signaling in perpetuating a 
hyperactive energy supply-and-demand cycle upon high-fat/high-choles-
terol (HF/HC) diet feeding.  The HF/HC diet induced several metabolic 
changes (1), including hypercholesterolemia, slight hypertriglyceridemia, 
slight hypertension (HTN), and, in some pigs, insulin resistance.  The HF/
HC diet may have increased free fatty acid (FFA) availability and total 
energy supply (2) to the myocardium.  By affecting various upstream medi-
ators, including Akt and AMPK, and increasing total mTOR and raptor 
levels (3), the HF/HC diet activated both mTORC1 and mTORC2 in myo-
cytes.  Myocardial energy demand was enhanced by mTORC1 (4), which 
promotes translation, the synthesis of contractile proteins, and enhances 
contractility.  mTORC1 also inhibited autophagy (5), potentially leading 
to the accumulation of misfolded proteins, mitochondrial dysfunction, and 
premature myocardial senescence.  mTORC2 potentiated this cycle by 
activating Akt, which transports more nutrients into the myocardium and 
further activates mTORC1.  These metabolic and signaling alterations 
induced by the HF/HC diet may increase the susceptibility of myocytes to 
ischemia-reperfusion (I/R) injury.
Figure 7. Hypercholesterolemia is associated with increased levels 
of hypertrophy-associated proteins, and a trend toward decreased 
autophagy in the myocardium. Representative western blots for β-actin, 
troponin I, troponin T, SERCA2 ATPase, α-tubulin, LC3B-I&II and GAPDH 
as a loading control in the left ventricle of hypercholesterolemic (HC) and 
normocholesterolemic (NC) pigs, and quantification of the data. Bands 
were rearranged from the original gel for clarity of presentation. Densities 
were calculated relative to total Ponceau S staining. The ratio of LC3B-II 
to I (LC3B-II/Ir) was calculated by dividing the density of the bottom band 
by that of the top on the LC3B blots. Data are expressed as mean ± SEM. 
*p < 0.05 versus control.
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Statistical analysis. Densitometry values were analyzed with 
the unpaired student’s t-test or Mann-Whitney U test when 
appropriate (SigmaStat, Systat Software, San Jose, CA), and Pearson 
or Spearman’s correlation coefficients with respective p values were 
calculated using GraphPad Prism 4 (GraphPad Software, La Jolla, 
CA). One control animal was excluded from the study using 
Dixon’s Q-test due to extremely high phosphorylation and total 
levels of many proteins measured in this study.
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